What is changing: The guidance on metformin regarding creatinine clearance and contrast has changed.
Rationale: The FDA has loosened the restrictions on who can receive metformin and has made new recommendations for which patients receiving contrast metformin should be held.
Planned “Go-Live” date is June 21, 2016.
Additional details:
• Metformin should be held for a patient with a GFR less than 30 mL/min.
• If the GFR acutely decreases to between 30 & 45 mL/min, a dose reduction should be considered.
• For patients receiving contrast, metformin should be held for at least 48 hours for patients whose GFR is less than 60 mL/min. Metformin should be re-evaluated and restarted after this 48 hours.
For concerns and questions, contact Matt Tanner by email or at 503-814-2048.